Progression of chronic kidney disease in non- dialysis patients
a retrospective cohort
DOI:
https://doi.org/10.1590/s2175-97902022e20249Keywords:
Chronic kidney disease, Disease progression, Drug utilization, Drug therapy, NephrologyAbstract
Evidence on factors associated with the progression of chronic kidney disease (CKD) is still under construction. The present study aimed to evaluate sociodemographic, clinical, and drug use factors associated with the progression of CKD. A retrospective cohort study was conducted with 193 patients with CKD stages 3A to 5- non-dialysis followed for three years in a Brazilian city. The outcome was the evolution to renal replacement therapy (RRT) or death. A total of 52.3 % (n = 101) were men and 83.4 % (n = 161) elderly. The median age was 72.0 years, and 22.3 % (n = 44) progressed to RRT or death, and the three-year mortality rate was 20.2 %. Participants exposed to angiotensin converting enzyme inhibitors or angiotensin II receptor blockers had a lower risk of progressing to the outcome (hazard ratio (HR) 0.25; p = 0.003) and higher survival (p = 0.022) when compared to those not exposed to these drugs. Age (HR 1.06;) and use of omeprazole (HR 6.25; CI; p <0.01) and hydrochlorothiazide (HR 2.80; p = 0.028) increased the risks of RRT or death. The results highlight the importance of rational management of pharmacotherapy for patients with CKD.
Downloads
References
Abensur, H. E-book (2011) - Biomarcadores na Nefrologia. Sociedade Brasileira de Nefrologia. Available in: Available in: https://arquivos.sbn.org.br/pdf/biomarcadores.pdf Access: May 15th, 2019.
» https://arquivos.sbn.org.br/pdf/biomarcadores.pdf
ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288(23):2981-97.
Bochud M. On the rationale of population screening for chronic kidney disease: a public health perspective. Public Health Rev. 2015;5(36):11.
Brown MJ, Palmer CR, Castaigne A, Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-72.
Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD. Outcomes of stage 3-5 chronic kidney disease before end- stage renal disease at a single center in Taiwan. Nephron Clin Pract. 2008;109(3):109-118.
Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006;2(2):80-91.
Costa CMFN, Silveira MR, Guerra Junior AA, Costa EA, Acurcio FA, Guibu IA, et al. Utilização de medicamento pelos usuários da atenção primária do Sistema Único de Saúde. Rev Saude Publica. 2017;51(2):18.
Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure - Re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10(2):165-9.
Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP, et al. Single-Nephron Glomerular Filtration in Healthy Adults. N Engl J Med. (2017);376(24):2349-2357.
Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet . 2013;382(9887):158-69.
Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose - 2017. Arq Bras Cardiol. 2017;109(2Supl.1):1-76.
Glassock R, Denic A, Rule AD. When kidneys get old: an essay on nephro-geriatrics. J Bras Nefrol. 2017;39(1):59-64.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med . 2004;351(13):1296-1305
Guedes JVM, Aquino JA, Castro TLB, Morais FA, Baldoni AO, Belo VS, et al. Omeprazole use and risk of chronic kidney disease evolution. Plos One. 2020;15(3):1-16.
Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019;39(4):443-453.
Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lee PC, et al. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study. Fam Pract. 2018;35(2):166-171.
Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73-87.
Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH, Jummaat F. Progression and outcomes of non-dialysis dependent chronic kidney disease patients: A single center longitudinal follow-up study. Nephrology (Carlton). 2017;22(1):25-34.
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med . 2008;148(1):30-48.
Lascasas JMSS, Fonseca I, Malheiro J, Santos S, Campos A, Castro A, et al. Demographic, clinical characteristics and cardiovascular disease burden in a Portuguese cohort of older chronic kidney disease patients. J Bras Nefrol. 2019;41(1):29-37.
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J. Proton pump inhibitor use and risk of chronic kidney disease. Jama Intern Med. 2016:176(2):238-246.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med . 1993;329(20):1456-62
Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827-47.
Mariani L, Stengel B, Combe C, Massy ZA, Reichel H, Fliser D, et al. The CKD outcomes and practice patterns study (CKDopps): Rationale and methods. Am J Kidney Dis. 2016;68(3):402-13.
Marinho AWGB, Penha AP, Silva MT, Galvão TF. Prevalência de doença renal crônica em adultos no Brasil: revisão sistemática da literatura. Cad Saúde Colet. 2017;25(3):379-388.
Ministério da Saúde (Brasil). Diretrizes Clínicas para o Cuidado ao paciente com Doença Renal Crônica - DRC no Sistema Único de Saúde. Brasília: Ministério da Saúde, 2014.
Morschel CF, Mafra D, Eduardo JCC. IBPs, hipomagnesemia, NIA, LRA e DRC. Braz J Nephrol. 2018;40(3):301-306.
Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg- Gresham JL, Eberhardt MS, et al. Centers for disease control and prevention chronic kidney disease surveillance team. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med . 2016;165(7):473-481.
National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3(1):1-150.
Pereira AC, Carminatti M, Fernandes NMS, Tirapani LS, Faria RS, Grincenkov FRS, et al. Association between laboratory and clinical risk factors and progression of the predialytic chronic kidney disease. J Bras Nefrol . 2012;34(1):68-75.
Peres DABP, Bettin TE. Dyslipidemia in patients with chronic kidney disease. Rev Soc Bras Clin Med. 2015;13(1):10-13.
Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6):7-16.
Sarmento LR, Fernandes PC, Pontes MX, Correia DBS, Chaves VCB, Carvalho CFA, et al. Prevalência das causas primárias de doença renal crônica terminal (DRCT) validadas clinicamente em uma capital do Nordeste brasileiro. J Bras Nefrol . 2018;40(2):130-135.
Savage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020;180(5):643-651.
SBD - Diretrizes da Sociedade Brasileira de Diabetes 2017- 2018. Organização José Egídio Paulo de Oliveira, Renan Magalhães Montenegro Junior, Sérgio Vencio. São Paulo: Editora Clannad, 2017.
Schaefer B, Wühl E. Educational paper: Progression in chronic kidney disease and prevention strategies. Eur J Pediatr. 2012;171(11):1579-88.
Silva GD, Acúrcio FA, Cherchiglia ML, Guerra JAA, Andrade EG. Medicamentos excepcionais para doença renal crônica: gastos e perfil de utilização em Minas Gerais, Brasil. Cad Saúde Pública. 2011;7(2):357-368.
Sociedade Brasileira de Nefrologia - SBN. Censo da Sociedade Brasileira de Nefrologia 2018. Available at: http://www.censo-sbn.org.br/censosAnteriores >. Acess: 02/04/2019.
» http://www.censo-sbn.org.br/censosAnteriores
Stengel B, Combe C, Jacquelinet C, Briançon S, Fouque D, Laville M, et al. The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. Nephrol Dial Transplant . 2014;29(8):1500-7.
Stengel B, Metzger M, Froissart M, Rainfray M, Berr C, Tzourio C, et al. Epidemiology and prognostic significance of chronic kidney disease in the elderly--the Three- City prospective cohort study. Nephrol Dial Transplant . 2011;26(10):3286-95.
Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268(5):456-67.
Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) . 2009;14(2):240-6.
United States Renal Data System (USRDS). Annual data report: atlas of end stage renal disease in the United States National Institutes of Health, Bethesda (Md), 2006.
Varallo FR, Nadai TR, Oliveira ARA, Mastroianni PC. Potential adverse drug events and nephrotoxicity related to prophylaxis with omeprazole for digestive disorders: A prospective cohort study. Clin Ther. 2018;40(6):973-982.
Webster CA, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet . 2017;389(10075):1238-1252.
Yang H, Juang SY, Liao KF. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019;147:67-75.
Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Devel Ther. 2017;24(11)1291-1299.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Funding data
-
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Grant numbers 001
